US 12,013,388 B2
Method and kit for single cell protein expression profiling of floorplate mesencephalic dopaminergic progenitor cells
Melanie Jungblut, Bergisch Gladbach (DE); Andreas Bosio, Cologne (DE); Sebastian Knöbel, Cologne (DE); Agnete Kirkeby, Hellerup (DK); and Malin Parmar, Lund (SE)
Assigned to Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach (DE)
Appl. No. 16/632,229
Filed by Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach (DE)
PCT Filed Jul. 16, 2018, PCT No. PCT/EP2018/069197
§ 371(c)(1), (2) Date Jan. 17, 2020,
PCT Pub. No. WO2019/016113, PCT Pub. Date Jan. 24, 2019.
Claims priority of application No. 17181588 (EP), filed on Jul. 17, 2017.
Prior Publication US 2020/0173983 A1, Jun. 4, 2020
Int. Cl. G01N 33/50 (2006.01); G01N 33/58 (2006.01)
CPC G01N 33/5005 (2013.01) [G01N 33/58 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method for obtaining and characterizing a composition of human dopaminergic progenitor cells, the method comprising:
a) differentiating a population of human pluripotent stem cells or progeny thereof into a preparation of neural progenitor cells;
b) maturing the preparation of neural progenitor cells into a cell composition that contains dopaminergic progenitor cells;
c) determining what percentage of cells in the composition expresses each of a panel of markers consisting of FOXA1, OTX2, PAX6, and NKX6.1, thereby obtaining a protein expression profile;
whereby the cell composition is characterized as having a desirable phenotype if the protein expression profile is as follows:
80 to 100% of said cells are positive for FOXA2,
80 to 100% of said cells are positive for OTX2,
less than 10% of said cells are positive for PAX6, and
less than 10% of said cells are positive for NKX6.1.